{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:56:59Z","timestamp":1788483419297,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1038\/s41433-020-01384-y","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T18:03:46Z","timestamp":1610129026000},"page":"3056-3063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of bevacizumab for vitreous haemorrhage in proliferative diabetic retinopathy with prior complete panretinal photocoagulation"],"prefix":"10.1038","volume":"35","author":[{"given":"Young Joo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-2758","authenticated-orcid":false,"given":"Sang Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwangsic","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5062-6392","authenticated-orcid":false,"given":"Joo Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"1384_CR1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00006982-200603000-00001","volume":"26","author":"RP Manzano","year":"2006","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257\u201361.","journal-title":"Retina"},{"key":"1384_CR2","first-page":"149","volume":"1","author":"AM El-Batarny","year":"2007","unstructured":"El-Batarny AM. Intravitreal bevacizumab treatment for retinal neovascularization and vitreous hemorrhage in proliferative diabetic retinopathy. Clin Ophthalmol. 2007;1:149\u201355.","journal-title":"Clin Ophthalmol"},{"key":"1384_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","volume":"26","author":"RF Spaide","year":"2006","unstructured":"Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275\u20138.","journal-title":"Retina"},{"key":"1384_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","volume":"131","author":"Diabetic Retinopathy Clinical Research Network.","year":"2013","unstructured":"Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131:283\u201393.","journal-title":"JAMA Ophthalmol"},{"key":"1384_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/IAE.0000000000001673","volume":"38","author":"E Chelala","year":"2018","unstructured":"Chelala E, Nehme J, El Rami H, Aoun R, Dirani A, Fadlallah A, et al. Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina. 2018;38:1127\u201333.","journal-title":"Retina"},{"key":"1384_CR6","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/eye.2013.200","volume":"27","author":"S Sinawat","year":"2013","unstructured":"Sinawat S, Rattanapakorn T, Sanguansak T, Yospaiboon Y, Sinawat S. Intravitreal bevacizumab for proliferative diabetic retinopathy with new dense vitreous hemorrhage after full panretinal photocoagulation. Eye. 2013;27:1391\u20136.","journal-title":"Eye"},{"key":"1384_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/08820538.2014.959198","volume":"29","author":"EK Deschler","year":"2014","unstructured":"Deschler EK, Sun JK, Silva PS. Side-effects and complications of laser treatment in diabetic retinal disease. Semin Ophthalmol. 2014;29:290\u2013300.","journal-title":"Semin Ophthalmol"},{"key":"1384_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2017.01.010","volume":"176","author":"RN Parikh","year":"2017","unstructured":"Parikh RN, Traband A, Kolomeyer AM, VanderBeek BL, Kim BJ, Maguire AM, et al. Intravitreal bevacizumab for the treatment of vitreous hemorrhage due to proliferative diabetic retinopathy. Am J Ophthalmol. 2017;176:194\u2013202.","journal-title":"Am J Ophthalmol"},{"key":"1384_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1097\/IAE.0b013e3181b094b7","volume":"29","author":"YH Huang","year":"2009","unstructured":"Huang YH, Yeh PT, Chen MS, Yang CH, Yang CM. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina. 2009;29:1134\u201340.","journal-title":"Retina"},{"key":"1384_CR10","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/jamaophthalmol.2014.287","volume":"132","author":"AR Bhavsar","year":"2014","unstructured":"Bhavsar AR, Torres K, Glassman AR, Jampol LM, Kinyoun JL, Diabetic Retinopathy Clinical Research Network. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol. 2014;132:889\u201390.","journal-title":"JAMA Ophthalmol"},{"key":"1384_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.29271\/jcpsp.2018.12.923","volume":"28","author":"W Ali","year":"2018","unstructured":"Ali W, Abbasi KZ, Raza A. Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy. J Coll Physicians Surg Pak. 2018;28:923\u20137.","journal-title":"J Coll Physicians Surg Pak"},{"key":"1384_CR12","first-page":"76","volume":"6","author":"A Dehghani","year":"2017","unstructured":"Dehghani A, Ghanbari H, Mahdizadeh A, Pourazizi M. Single-dose intravitreal bevacizumab after complete panretinal photocoagulation in proliferative diabetic retinopathy: an effective adjunctive treatment. Med Hypothesis Discov Innov Ophthalmol. 2017;6:76\u201381.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"1384_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.12669\/pjms.331.11497","volume":"33","author":"M Sameen","year":"2017","unstructured":"Sameen M, Khan MS, Mukhtar A, Yaqub MA, Ishaq M. Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy. Pak J Med Sci. 2017;33:142\u20135.","journal-title":"Pak J Med Sci"},{"key":"1384_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1755-3768.2009.01622.x","volume":"89","author":"G Schmidinger","year":"2011","unstructured":"Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U. Repeated intravitreal bevacizumab (Avastin((R))) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011;89:76\u201381.","journal-title":"Acta Ophthalmol"},{"key":"1384_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1136\/bjo.2007.127142","volume":"92","author":"JF Arevalo","year":"2008","unstructured":"Arevalo JF, Maia M, Flynn HW Jr., Saravia M, Avery RL, Wu L, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1384_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1755-3768.2008.01225.x","volume":"87","author":"JB Jonas","year":"2009","unstructured":"Jonas JB, Schmidbauer M, Rensch F. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol. 2009;87:571\u20132.","journal-title":"Acta Ophthalmol"},{"key":"1384_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICB.0b013e3181578dd8","volume":"3","author":"ME Torres-Soriano","year":"2009","unstructured":"Torres-Soriano ME, Reyna-Castelan E, Hernandez-Rojas M, Garcia-Aguirre G, Kon-Jara V, Diaz-Rubio JL, et al. Tractional retinal detachment after intravitreal injection of bevacizumab in proliferative diabetic retinopathy. Retin Cases Brief Rep. 2009;3:70\u20133.","journal-title":"Retin Cases Brief Rep"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01384-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01384-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T18:05:39Z","timestamp":1642529139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-020-01384-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1038\/s41433-020-01384-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"27 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}